Quick Answer
FATE THERAPEUTICS INC reported Research And Development Expense of $107.83 million for the year ending 2025.
- FATE THERAPEUTICS INC showed a decrease of -20.1% in Research And Development Expense from 2024 to 2025.
- This data is from FATE THERAPEUTICS INC's annual report (Form 10-K), filed with the SEC on February 26, 2026.
- XBRL data for this metric is available from 2011 to 2025 (15 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q3 2012: $3.32 million | Q1 2013: $2.53 million | Q2 2013: $3.07 million | Q3 2013: $3.38 million | Q1 2014: $4.52 million | Q2 2014: $3.97 million | Q3 2014: $4.08 million | Q1 2015: $4.57 million | Q2 2015: $4.86 million | Q3 2015: $5.00 million | Q1 2016: $6.64 million | Q2 2016: $6.78 million | Q3 2016: $6.80 million | Q1 2017: $7.97 million | Q2 2017: $7.93 million | Q3 2017: $8.58 million | Q1 2018: $11.48 million | Q2 2018: $16.82 million | Q3 2018: $13.64 million | Q1 2019: $17.73 million | Q2 2019: $21.63 million | Q3 2019: $23.20 million | Q1 2020: $29.28 million | Q2 2020: $26.67 million | Q3 2020: $30.69 million | Q1 2021: $44.85 million | Q2 2021: $48.02 million | Q3 2021: $53.13 million | Q1 2022: $72.14 million | Q2 2022: $81.31 million | Q3 2022: $79.82 million | Q1 2023: $65.63 million | Q2 2023: $40.88 million | Q3 2023: $34.28 million | Q1 2024: $32.14 million | Q2 2024: $34.60 million | Q3 2024: $34.65 million | Q1 2025: $29.14 million | Q2 2025: $27.43 million | Q3 2025: $25.84 million.
- Over the full 15 years of available data (2011 to 2025), FATE THERAPEUTICS INC's Research And Development Expense has grown by 993.8%.
- Historical annual values: Fiscal year 2025: $107.83 million | Fiscal year 2024: $135.00 million | Fiscal year 2023: $172.60 million | Fiscal year 2022: $320.45 million | Fiscal year 2021: $215.52 million | Fiscal year 2020: $125.62 million | Fiscal year 2019: $87.77 million | Fiscal year 2018: $56.02 million | Fiscal year 2017: $34.36 million | Fiscal year 2016: $26.45 million | Fiscal year 2015: $19.86 million | Fiscal year 2014: $16.44 million | Fiscal year 2013: $12.01 million | Fiscal year 2012: $12.00 million | Fiscal year 2011: $9.86 million.
- Data sourced from SEC EDGAR public filings as of August 5, 2026.
Last verified: